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Abstract: The Transient Receptor Potential Ankyrin 1 (TRPA1) cation channel expressed on
capsaicin-sensitive afferents, immune and endothelial cells is activated by inflammatory mediators
and exogenous irritants, e.g., endotoxins, nicotine, crotonaldehyde and acrolein. We investigated its
involvement in acute and chronic pulmonary inflammation using Trpa1 gene-deleted (Trpa1−/−) mice.
Acute pneumonitis was evoked by intranasal Escherichia coli endotoxin (lipopolysaccharide: LPS)
administration, chronic bronchitis by daily cigarette smoke exposure (CSE) for 4 months. Frequency,
peak inspiratory/expiratory flows, minute ventilation determined by unrestrained whole-body
plethysmography were significantly greater, while tidal volume, inspiratory/expiratory/relaxation
times were smaller in Trpa1−/− mice. LPS-induced bronchial hyperreactivity, myeloperoxidase activity,
frequency-decrease were significantly greater in Trpa1−/− mice. CSE significantly decreased tidal
volume, minute ventilation, peak inspiratory/expiratory flows in wildtypes, but not in Trpa1−/− mice.
CSE remarkably increased the mean linear intercept (histopathology), as an emphysema indicator after
2 months in wildtypes, but only after 4 months in Trpa1−/− mice. Semiquantitative histopathological
scores were not different between strains in either models. TRPA1 has a complex role in basal
airway function regulation and inflammatory mechanisms. It protects against LPS-induced acute
pneumonitis and hyperresponsiveness, but is required for CSE-evoked emphysema and respiratory
deterioration. Further research is needed to determine TRPA1 as a potential pharmacological target
in the lung.
Keywords: bronchitis; cigarette smoke; COPD; emphysema; LPS; pneumonitis; whole
body plethysmography
1. Introduction
The Transient Receptor Potential Ankyrin 1 (TRPA1) receptor is the sole member of the “ankyrin”
subfamily of the Transient Receptor Potential (TRP) receptors in mammals. It is predominantly
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expressed on capsaicin-sensitive peptidergic sensory nerves densely innervating the lungs [1,2].
TRPA1 is a large transmembrane protein forming a ligand-gated non-selective cation channel [3,4].
TRPA1 is activated by several exogenous stimuli, such as bacterial endotoxin [5] and environmental
irritants like acrolein, crotonaldehyde, nicotine and isocyanates [6–10], found in cigarette smoke,
wood smoke, diesel exhaust and tear gas [6,7,10–13]. Moreover, several endogenous mediators
produced during inflammation and oxidative stress, such as lipid peroxidation products, e.g.,
4-hydroxynonenal (HNE) and 4-oxo-2-nonenal (4-ONE) [14–16], reactive oxygen species (ROS) [17],
hydrogen sulfide, bradykinin and prostanoids stimulate TRPA1 [18–22]. Electrophilic compounds
activate the receptor by covalently binding to the reactive cysteine residues at the intracellular
N-terminal region [23–26]. Bradykinin and prostaglandins sensitize TRPA1 [22,27] through protein
kinase A (PKA)-mediated phosphorylation [28,29]. Moreover, TRPA1 is also involved in protease
activated receptor 1 (PAR1)/Gq-mediated increase of the intracellular Ca2+-level [30,31].
Pro-inflammatory sensory neuropeptides, e.g., substance P (SP) and calcitonin gene-related
peptide (CGRP) are released in response to TRPA1 activation leading to neurogenic inflammation
(vasodilatation and plasma protein extravasation) [32]. Simultaneously with these pro-inflammatory
mediators, anti-inflammatory neuropeptides, e.g., somatostatin and pituitary adenylate cyclase
activating polypeptide are also released from the same terminals counteracting the inflammatory
process [33,34].
TRPA1 is also expressed on several non-neuronal cells [35], e.g., keratinocytes, macrophages and
CD4+ lymphocytes [36–38], epidermal melanocytes, fibroblasts [39,40], urothelial and endothelial cells,
as well as primary human osteoarthritic chondrocytes [41–43]. In the airways, TRPA1 is expressed
on fibroblasts, tracheal, bronchial and alveolar epithelial cells, bronchial smooth muscle cells (SMC),
as well as lymphocytes [17,44–50].
Due to its polymodal chemosensor function and its wide expression pattern, TRPA1 has been
addressed as having a key role in physiological and pathophysiological processes, particularly in
neuro-immune interactions [51–53]. It is suggested to be a particularly important chemical sensor in
the respiratory system, playing a role in physiological (protective reflexes, cough and sneeze) and
pathophysiological responses (inflammation, bronchial hyperreactivity) [54–56]. Although increasing
evidence suggests TRPA1 involvement in the pathogenesis of chronic obstructive pulmonary disease
(COPD), asthma, chronic cough, cystic fibrosis etc., pointing to the important therapeutic potential
of TRPA1 in the pharmacological treatment of chronic pulmonary diseases [26,46,54,57–62], there are
few in vivo data concerning its function in airway inflammation. Therefore, the results are far from
being conclusive and more information is needed to determine the significance of TRPA1 as a possible
pharmacological target in inflammatory lung disease, pneumonitis and COPD.
Therefore, in the present study we investigated the involvement of TRPA1 in the in vivo models
of endotoxin (lipopolisaccharide: LPS)-induced acute and cigarette smoke exposure-induced chronic
pulmonary inflammation with the help of TRPA1 wildtype (Trpa1+/+) and gene-deficient (Trpa1−/−) mice.
2. Results
2.1. Differences in Basal Airway Function Parameters of Trpa1+/+ and Trpa1−/− Mice
Under intact conditions, frequency (f), minute ventilation (MV), peak inspiratory flow (PIF)
and peak expiratory flow (PEF) were significantly greater, tidal volume (TV), inspiratory time (Ti),
expiratory time (Te) and relaxation time (RT) were significantly smaller, while no difference was
detected in the enhanced pause (Penh) of Trpa1−/− mice compared to their wildtype counterparts,
measured by unrestrained whole body plethysmography (WBP) (Figure 1).
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Figure 1. Comparison of the basal airway functions of intact Trpa1+/+ and Trpa1−/− mice measured by 
unrestrained whole-body plethysmography. (A) Breathing frequency (f), (B) tidal volume (TV), (C) 
minute ventilation (MV), (D) inspiratory time (Ti), (E) expiratory time (Te), (F) relaxation time (RT), 
(G) peak inspiratory flow (PIF) and (H) peak expiratory flow (PEF) were measured in conscious, 
spontaneously breathing mice. (I) Enhanced pause (Penh) correlating with bronchial responsiveness 
was assessed by the nebulization of the muscarinic receptor agonist, carbachol. Values represent the 
means ± SEM, n = 30–35 mice/group; Student’s t-test for unpaired comparison; * p < 0.05; *** p < 0.001. 
2.2. Endotoxin-Induced Bronchial Hyperreactivity is Greater in Trpa1−/− Mice 
Bronchial responsiveness characterized by the Penh parameter significantly and concentration-
dependently elevated in the Trpa1−/− mice in response to increasing concentrations of the muscarinic 
receptor agonist carbachol 24 h after the administration of intranasal LPS. This indicates the 
development of inflammatory airway hyperreactivity, which was significantly greater in the TRPA1-
deficient mice compared to the LPS-treated wildtypes (Figure 2A). 
LPS inhalation significantly reduced basal f in both strains. In response to carbachol, f did not 
change in Trpa1+/+ mice, but it significantly declined in a concentration-dependent manner in the 
Trpa1−/− ones, being significantly lower compared to the wildtypes at 11 and 22 mM carbachol stimuli 
(Figure 2B). 
Interestingly, the mild, although significant breathing frequency difference between the 
wildtype and knockout groups found under intact conditions was not observable in this model, most 
probably because of the different study setting and the use of phosphate buffer saline (PBS) in the 
control group. 
Figure 1. Comparison of the basal airway functions of intact Trpa1+/+ and Trpa1−/− mice measured
by unrestrained whole-body plethysmography. (A) Breathing frequency (f), (B) tidal volume (TV),
(C) minute ventilation (MV), (D) inspiratory time (Ti), (E) expiratory time (Te), (F) relaxation time
(RT), (G) peak inspiratory flow (PIF) and (H) peak expiratory flow (PEF) were measured in conscious,
spontaneously breathing mice. (I) Enhanced pause (Penh) correlating with bronchial responsiveness
was assessed by the nebulization of the muscarinic receptor agonist, carbachol. Values represent the
means ± SEM, n = 30–35 mice/group; Student’s t-test for unpaired comparison; * p < 0.05; *** p < 0.001.
2.2. Endotoxin-Induced Bronchial Hyperreactivity is Greater in Trpa1−/− Mice
Bronchial responsiveness characterized by the Penh parameter significantly and
concentration-depe dently elevated in the Trpa1−/− mice in respon e to increasing concentrations of
the muscarinic rec ptor agonist carbachol 24 h after the admini tration of i tr nasal LPS. This indicates
the development of inflammatory airway hyperreactivity, which was significantly greater in the
TRPA1-d ficient mice compared to the LPS-treated wildtypes (Figure 2A).
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Figure 2. Inflammatory airway hyperreactivity: (A) carbachol-induced bronchoconstriction and (B) 
changes in breathing frequency. Carbachol-evoked bronchoconstriction remarkably increased, and 
the decrease in breathing frequency was significantly greater in Trpa1−/− mice 24 h after LPS 
administration, but not in the wildtypes. Values represent the means ± SEM, n = 5–10 mice/group; 
two-way ANOVA followed by Tukey’s post-test; + p < 0.05, ++ p < 0.005, +++ p < 0.001 vs. PBS-treated 
respective group; * p < 0.05 vs. LPS-treated Trpa1+/+. 
2.3. Endotoxin-Induced Histological Alterations Show No Difference in the Case of TRPA1-Deficiency 
In comparison to the PBS-treated mouse groups (Figure 3A,B) LPS administration induced 
remarkable oedema formation and inflammatory cell infiltration (Figure 3C,D) in the lung tissue. 
Based on the semiquantitative histopathological evaluation perivascular/peribronchial oedema and 
neutrophil granulocyte infiltration (Figure 4A) were significantly higher 24 h after LPS treatment, 
and the extent of goblet cell hyperplasia also increased, although not significantly. There was no 
statistical difference in the extent of endotoxin-induced airway inflammation scores between Trpa1+/+ 
and Trpa1−/− mice (Figure 4A,B). 
  
Figure 2. Inflammatory airway hyperreactivity: (A) carbachol-induced bronchoconstriction and
(B) changes in breathing frequency. Carbachol-evoked bronchoconstriction remarkably increased,
and the decrease in breathing frequency was significantly greater in Trpa1−/− mice 24 h after LPS
administratio , ut not in the wildtypes. Values represent th means ± SEM, n = 5–10 mice/group;
two-way ANOVA followed by Tukey’s post-test; + < 0.05, ++ p < 0.005, +++ p < 0.00 vs. PBS-treated
respective group; * p < 0.05 vs. LPS-treated Trpa1+/+.
LPS inhalation significantly reduced basal f in both strains. In response to carbachol, f did not
change in Trpa1+/+ mice, but it significa tly declined in a concentration-dependent ma ner in the
Trpa1−/− ones, being significantly lower compared to the wildtypes at 11 and 22 mM carbachol stimuli
(Figure 2B).
Interestingly, the mild, although significant breathing frequency difference between the wildtype
and knockout groups found under intact conditions was not observable in this model, most probably
because of the different study setting and the use of phosphate buffer saline (PBS) in the control group.
2.3. Endotoxin-Induced Histological Alterations Show No Difference in the Case of TRPA1-Deficiency
In comparison to the PBS-treated mouse groups (Figure 3A,B) LPS administration induced
remarkable oedema formation and inflammatory cell infiltration (Figure 3C,D) in the lung tissue.
Based on the semiquantitative histopathological evaluation perivascular/peribronchial oedema and
neutrophil granulocyte infiltration (Figure 4A) were significantly higher 24 h after LPS treatment,
and the extent of goblet cell hyperplasia also increased, although not significantly. There was no
statistical difference in the extent of endotoxin-induced airway inflammation scores between Trpa1+/+
and Trpa1−/− mice (Figure 4A,B).
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Figure 3. Representative histological pictures of LPS-induced pulmonary alterations. Compared to 
the PBS-treated (A) Trpa1+/+ and (B) Trpa1−/− control groups, the lung tissue of LPS-treated (C) Trpa1+/+ 
and (D) Trpa1−/− mice exhibited remarkable perivascular and peribronchial oedema, neutrophil 
granulocyte accumulation, macrophage infiltration and goblet cell hyperplasia (hematoxylin-eosin 
staining; 200× magnification; a: alveolus, b: bronchiolus, v: venula, oed: oedema). 
Figure 3. R presentative histological pictures of LPS-induced pulmonary alterations. Co par t the
-tr t ( ) Trpa1+/+ ( ) rpa1−/ c tr l r , t l tissue of LPS-treated (C) Trpa1+/ and
(D) Trpa1−/− mice exhibited remarkable perivascul r and peribronchial oedema, neutrophil granulocyte
accumulation, macrophage infiltr tion and goblet cell hyperplasia (hematoxylin-eosin staining; 200× g
ma nification; a: alve lus, b: bronchiolus, v: venula oed: oedema).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 21 
 
 
Figure 4. Semiquantitative histopathological evaluation and determination of the myeloperoxidase 
(MPO) activity of the lung 24 h after LPS inhalation. No significant difference was observed in the (A) 
detailed and (B) composite scores of histopathological inflammatory parameters between the Trpa1+/+ 
and Trpa1−/− groups. Boxplots represent the minimum, first quartile, mean, third quartile and 
maximum values, n = 7–13/group, Kruskal–Wallis followed by Dunn’s post-test; + p < 0.05, ++ p < 0.005, 
+++ p < 0.001 vs. PBS-treated Trpa1+/+. (C) LPS administration increased myeloperoxidase activity in the 
lung, which was significantly elevated in Trpa1−/− compared to the wildtypes. Values represent the 
means ± SEM, n = 5–8 mice/group; one-way ANOVA followed by Bonferroni’s post-test; +++ p < 0.001 
vs. PBS-treated respective group; ** p < 0.01 vs. LPS-treated Trpa1+/+. 
2.4. Endotoxin-Induced Myeloperoxidase Activity in the Lung is Greater in Trpa1−/− Mice 
Myeloperoxidase (MPO) enzyme activity correlating with the activated neutrophil granulocytes 
and macrophages increased 24 h after LPS-inhalation in both strains, however it was significantly 
greater in Trpa1−/− mice compared to the wildtypes (Figure 4C). 
2.5. Chronic Cigarette Smoke Induces Respiratory Function Alterations in Trpa1+/+, but not in Trpa1−/− Mice 
Figure 4. Cont.
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Figure 4. Semiquantitative histopathological evaluation and determination of the myeloperoxidase
(MPO) activity of the lung 24 h after LPS inh lation. No significant d fference was observed in the
(A) detailed and (B) composite scores of hist patholo ical i flammatory p rameters between the
Trpa1+/+ and Trpa1−/− groups. Boxplots represent the mini um, first qu rtile, mean, third quartile and
maximum values, n = 7–13/group, Kruskal–Wallis followed by Dunn’s post-test; + p < 0.05, ++ p < 0.005,
+++ p < 0.001 vs. PBS-treated Trpa1+/+. (C) LPS administration increased myelo eroxidase activity in
the lung, which was significantly elevated in Trpa1−/− c mpared to the wildtypes. Values represent the
means ± SEM, n = 5–8 mice/group; one-way ANOVA followed by Bonferroni’s post-test; +++ p < 0.001
vs. PBS-treated respective gr ; ** p < 0.01 vs. LPS-treated Trpa1+/+.
2.4. Endotoxin-Induced Myeloperoxidase Activity in the Lung is Greater in Trpa1−/− Mice
Myeloperoxidase (MPO) enzyme activity correlating with the activ ted neutrophil granulocytes
and macrophages increased 24 h after LPS-inhalation in both strains, however it was significantly
greater in Trpa1−/− mice compared to the wildtypes (Figure 4C).
2.5. Chronic Cigarette Smoke Induces Respiratory Function Alterations in Trpa1+/+, but not in Trpa1−/− Mice
Respirato y functions wer measured in a foll w-up design before and at the e d of each month
in the 4-month long protocol of cigarette smoke exposure (CSE). CSE induced a gradual and significant
decrease in TV, MV, PIF and PEF in Trpa1+/+ mice with a peak at 3 months, which was not present in
the Trpa1−/− animals (Figure 5). The significant differences in f, Ti, Te and RT measured in the Trpa1−/−
mice were attributable to the significant differences between the wildtype and gene-deficient mice
observed already in the intact animals, before CSE.
Int. J. Mol. Sci. 2020, 21, 4109 7 of 21
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 21 
 
Respiratory functions were measured in a follow-up design before and at the end of each month 
in the 4-month long protocol of cigarette smoke exposure (CSE). CSE induced a gradual and 
significant decrease in TV, MV, PIF and PEF in Trpa1+/+ mice with a peak at 3 months, which was not 
present in the Trpa1−/− animals (Figure 5). The significant differences in f, Ti, Te and RT measured in 
the Trpa1−/− mice were attributable to the significant differences between the wildtype and gene-
deficient mice observed already in the intact animals, before CSE. 
 
Figure 5. Respiratory functions during the 4 months of cigarette smoke exposure. (B) Tidal volume 
(TV), (C) minute ventilation (MV), (G) peak inspiratory flow (PIF) and (H) peak expiratory flow (PEF) 
significantly decreased after CSE with a peak at 3 months in Trpa1+/+ mice. The significant strain 
differences in (A) frequency, (D) inspiratory time (Ti), (E) expiratory time (Te) and (F) relaxation time 
(RT) observed already in intact mice were not influenced by CSE. (I) Enhanced pause did not show 
any differences either by treatment or by strain. Values represent means ± SEM, n = 6–7 mice/group; 
two-way ANOVA followed by Tukey’s post-test; + p < 0.05, ++ p < 0.005, +++ p < 0.001 vs. PBS-treated 
respective group; * p < 0.05, ** p < 0.005, *** p < 0.001 vs. LPS-treated Trpa1+/+. 
2.6. CSE-Induced Inflammatory Histopathological Alterations are Similar in Trpa1+/+ and Trpa1−/− Mice 
After one month of CSE remarkable perivascular oedema developed (Figure 6C,E) that 
significantly decreased by time in both strains, and almost completely resolved at the end of the 4th 
month (Figure 7A). However, the accumulation of perivascular and peribronchial, as well as 
interstitial neutrophil granulocytes, macrophages and lymphocytes remained moderately increased 
throughout the experimental protocol (Figure 7B,C). At the end of the 3rd month of CSE, structural 
destruction characteristic to emphysema (Figure 6G–J) already developed. 
Figure 5. Respiratory functions during the 4 months of cigarette smoke exposure. (B) Tidal volume
(TV), (C) minute ventilation (MV), (G) peak inspiratory flow (PIF) and (H) peak expiratory flow (PEF)
significantly decreased after CSE with a peak at 3 months in Trpa1+/+ mice. The significant strain
differences in (A) frequency, (D) inspiratory time (Ti), (E) expiratory time (Te) and (F) relaxation time
(RT) observed already in intact mice were not influenced by CSE. (I) Enhanced pause did not show
any differences either by treatment or by strain. Values represent means ± SEM, n = 6–7 mice/group;
two-way ANOVA followed by Tukey’s post-test; + p < 0.05, ++ p < 0.005, +++ p < 0.001 vs. PBS-treated
respective group; * p < 0.05, ** p < 0.005, *** p < 0.001 vs. LPS-treated Trpa1+/+.
2.6. CSE-Induced Inflammatory Histopathological Alterations are Similar in Trpa1+/+ and Trpa1−/− Mice
After one month of CSE remarkable perivascular oedema developed (Figure 6C,E) that significantly
decreas d by ti e in both strains, nd almost comp etely resolve at the end of the 4th month
(Figure 7A). However, the accumulation of periv scular and p ribronchial, as w ll as interstitial
neu roph l g anulocytes, mac op ages and lymphocytes emained moderately increased throughout
th experimental protocol (Figure 7B,C). At th end of the 3rd month of CSE, structura dest uction
characteristic to emphysema (Figure 6G–J) already developed.
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Figure 6. Representative histological pictures of the lungs of Trpa1+/+ (A, C, E, G, I) and Trpa1−/− (B, D, 
F, H, J) mice under intact conditions (A,B), and after 1–4 months of CSE (C–J). One month of CSE 
induced a perivascular and peribronchial oedema formation associated with inflammatory cell 
infiltration, that gradually subsided over the 4-month long protocol. After the 3rd month of CSE, 
emphysema formation was observed in both wildtype and gene-deficient mice. (hematoxylin-eosin 
staining; 200× magnification; a: alveolus, b: bronchiolus, v: venula, oed: oedema, e: emphysema). 
Figure 6. Represe tati e hist logical pictures of the lungs of Trpa1+/+ (A,C,E,G,I) and Trpa1−/−
(B,D,F,H,J) mice under intact conditions (A,B), and after 1–4 months of CSE (C–J). One month of
CSE induced a perivascular and peribronchial oedema formation associated with inflammatory cell
infiltration, that gradually subsided over the 4-month long protocol. After the 3rd month of CSE,
emphysema formation was observed in both wildtype and gene-deficient mice. (hematoxylin-eosin
staining; 200× g magnification; a: alveolus, b: bronchiolus, v: venula, oed: oedema, e: emphysema).
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peribronchial, as well as interstitial (B) neutrophil granulocytes, (C) macrophages and lymphocytes 
did not differ in either groups significantly. Boxplots represent the minimum, first quartile, mean, 
third quartile and maximum values, n = 5–13/group, Kruskal–Wallis followed by Dunn’s post-test; + 
p < 0.05, ++ p < 0.005 vs. 1st month of CSE. 
2.7. Cigarette Smoke-Induced Emphysema Develops Earlier in Trpa1+/+ Mice 
Emphysema was quantified by in vivo microCT by the ratio of the low attenuation area (LAA) 
and total lung volume (TLV) before and after 2 and 4 months of CSE. The ratio correlating with the 
extent of air-filled regions did not show alterations either by CSE treatment or time (Figure 8A). 
However, the more sensitive mean linear intercept (Lm) measurement revealed that in Trpa1+/+ mice 
emphysema already started to develop at an earlier timepoint compared to the gene-deleted 
counterparts, Lm was significantly increased in the wildtypes after 2 months of CSE, however, not in 
the Trpa1−/−. At the end of the 4th month, Lm was elevated in both strains exposed to CS (Figure 8F). 
Figure 7. Semiquantitative evaluation of the histopathological changes of the lung after chronic
cigarette smoke exposure. (A) Perivascular/peribronchial oedema developed after 1 month of
CSE, which significantly decreased by time in both strains. The accumulation of perivascular and
peribronchial, as well as interstitial (B) neutrophil granulocytes, (C) macrophages and lymphocytes
did not differ in either groups significantly. Boxplots represent the minimum, first quartile, mean,
third quartile and maximum values, n = 5–13/group, Kruskal–Wallis followed by Dunn’s post-test;
+ p < 0.05, ++ p < 0.005 vs. 1st month of CSE.
2.7. Cigarette Smoke-Induced Emphysema Develops Earlier in Trpa1+/+ Mice
Emphysema was quantified by in vivo microCT by the ratio of the low attenuation area (LAA) and
total lung volume (TLV) before and after 2 and 4 months of CSE. The rati corr lating with the extent
of air-filled regions did not show alterations either by CSE treatment or time (Figure 8A). Howev r,
th m re sensitive mean linear i tercept (Lm) measur ment revealed hat in Trpa1+/+ ice emphysema
already started to develop at an earlier timepoint compared to the gene-delet counterparts, L was
significantly increased in he wildtyp s after 2 months of CSE, however, not in the Trpa1−/−. At th nd
f th 4th month, Lm was elevated in both strains exposed to CS (Figure 8F).
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Figure 8. Quantitative evaluation of emphysema. (A) LAA/TLV ratio correlating with air-filled 
regions of the lungs exposed to CSE showed no significant alterations. Representative microCT 
pictures of lungs (B,D) before and (C,E) after 4 months of CSE in Trpa1+/+ and Trpa1−/− mice, 
respectively. (F) Microscopic quantitative assessment of Lm showed a significant increase in Trpa1+/+ 
already after 2 months of CSE, but not in the Trpa1−/−. Values represent means ± SEM, n = 6–7 
mice/group; repeated measures two-way ANOVA followed by Tukey’s post-test. Representative 
microscopic pictures of (G) Trpa1+/+ and (H) Trpa1−/− mouse lung tissues after 2 months of CSE. Values 
represent means ± SEM, n = 60–100 measurements/group; two-way ANOVA followed by Tukey’s 
post-test; ++ p < 0.005, +++ p < 0.001 vs. PBS-treated respective group; * p < 0.05 vs. CSE-treated Trpa1+/+. 
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2.8. Chronic Cigarette Smoke-Induced Inflammatory Cell Accumulation in the BALF Shows No Strain 
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in the bronchoalveolar lavage fluid (BALF) of both Trpa1+/+ and Trpa1−/− mice. In agreement with our 
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There was no biologically relevant difference between the wildtype and gene-deficient mice in either 
inflammatory cell component (Figure 9). 
Figure 8. Quantitative evaluation of emphysema. (A) LAA/TLV ratio correlating with air-filled regions
of the lungs exposed to CSE showed no significant alterations. Representative microCT pictures of lungs
(B,D) before and (C,E) after 4 months of CSE in Trpa1+/+ and Trpa1−/− mice, respectively. (F) Microscopic
quantitative assessment of Lm showed a significant increase in Trpa1+/+ already after 2 months of
CSE, but not in the Trpa1−/−. Values represent means ± SEM, n = 6–7 mice/group; repeated measures
two-way ANOVA followed by Tukey’s post-test. Representative microscopic pictures of (G) Trpa1+/+
and (H) Trpa1−/− mouse lung tissues after 2 months of CSE. Values represent means ± SEM, n = 60–100
measurements/group; two-way ANOVA followed by Tukey’s post-test; ++ p < 0.005, +++ p < 0.001 vs.
PBS-treated respective group; * p < 0.05 vs. CSE-treated Trpa1+/+. (The blue circle indicates the region
of interest in which Lm was measured. The measured chord lengths represented by blue lines were
expressed in µm on the scanned slides and labelled in yellow.).
2.8. Chronic Cigarette Smoke-Induced Inflammatory Cell Accumulation in the BALF Shows No
Strain Difference
CSE induced massive accumulations of granulocytes, macrophages and lymphocytes measured
in the bronchoalveolar lavage fluid (BALF) of both Trpa1+/+ and Trpa1−/− mice. In agreement with our
previous findings [63], the number of inflammatory cells reduced by the end of the 3rd month of CSE.
There was no biologically relevant difference between the wildtype and gene-deficient mice in either
inflammatory cell component (Figure 9).
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Figure 9. Number of inflammatory cells in the bronchoalveolar lavage fluid (BALF) after 2–3 months
of CSE in Trpa1+/+ and Trpa1−/− mice. After the peak of inflammatory cell infiltration at a 2-month
timepoint, the number of (A) granulocytes, (B) macrophages and (C) lymphocytes remarkably decreased
by the end of the 3rd month in both Trpa1+/+ and Trpa1−/− mice. Values represent means ± SEM, n = 6–7
mice/group; two-way ANOVA followed by Tukey’s post-test.
3. Discussion and Conclusion
We provide here the first evidence that the TRPA1 channel has a complex role in basal airway
function regulation and inflammatory mechanisms. It protects against LPS-induced acute pneumonitis
and hyperresponsiveness, but triggers chronic CSE-evoked emphysema formation and respiratory
deterioration (Table 1).
Table 1. The complex regulatory role of TRPA1 in acute and chronic airway inflammation (ns:
non-significant; arrows indicate change compared to control PBS-treated or non-inflamed intact mice,
++ p < 0.005, +++ p < 0.001; asterisks indicate strain difference, * p < 0.05, ** p < 0.005 vs. Trpa1+/+).
Endotoxin-Induced Acute
Inflammation
Trpa1+/+ Trpa1−/− Trpa1+/+ vs. Trpa1−/−
LPS-Treated InflamedCompared to PBS- e ted Control
Bronchial hyperreactivity ns. ↑(++) *
Myeloperoxidase activity ns. ↑(+++) **
Inflammatory histopathological changes ↑(++) ns ns
CSE-induced Chronic Inflammation
Trpa1+/+ Trpa1−/− Trpa1+/+ vs. Trpa1−/−
CSE-Treated InflamedCompared to Intact Control
TV, MV, PIF, PEF ↓(++/+++) ns *
Oedema ↑ ↑ ns.
Inflammatory cell infiltration ↑ ↑ ns.
E physema earlier later *
Increasing data have suggested the involvement of the TRPA1 receptor in the pathophysiological
mechanisms of several airway diseases, such as asthma, COPD and allergic/irrita ive
cough [7,46,56–60,62,64–67], but little is known about its activation mechanisms and its potential
as a drug rget in lung inflammation is still con roversial. Our results demonstrating see ingly
op si g regulatory functions of TRPA1 in the acute and chr nic models can be explained by its
multiple l calizations th might evoke different responses. Neuronal TRPA1 in the airw ys is
expressed almost exclusively on vagal afferents that are a subpopulation of sensory afferents. It is
co-localized with Transient Receptor Pot ial Vanilloid 1 (TRPV1) on capsaicin-sensi ive vagal
bronchopulmonary nociceptive C-fibers origin ting from the jugular g nglion. Most of these
peptidergic bronchopulmonary -fibers modul te the inflammatory process and induce defensive
r flexes, shallow breathing, mucus secretion [68,69]. However, TRPA1-mediated effects via th se sory
trigeminal fferentation of the upper airways also might c ntribute to our results in both models [70].
Be ides the neuron l xpression, TRPA1 is also located on epithelial, inflammato y and bronchial
smooth muscl cell [6,47,48,50].
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The virtually contradicting role of TRPA1 might also be explained by the very distinct
pathophysiological mechanisms of the LPS and CSE models involving different signaling pathways
in different cell types. Moreover, endotoxin and cigarette smoke components are able to directly
activate TRPA1 among other exogenous irritants reaching the airways, besides a variety of endogenous
inflammatory mediators (protons, hydrogen peroxide, prostaglandins etc.) [5,8,10,18,22].
Direct interactions between endotoxins and TRPA1 [71,72] has been described in LPS-induced
acute inflammatory pain, CGRP-release and vascular response that developed via the activation of
TRPA1 on nociceptive sensory fibers, independently from TLR4 signaling [5]. The TRPA1 agonist
cinnamaldehyde exerts complex immunomodulatory effects on LPS-induced systemic inflammatory
response syndrome [73]. TRPA1 mediates the LPS-induced inflammatory responses in primary human
osteoarthritic fibroblast-like synoviocytes [74]. The role of TRPA1 as an LPS sensor is suggested to be
evolutionarily conserved [75], that occurs via mechanical modifications of the plasma lipid membrane.
Interestingly, Escherichia coli (E. coli) LPS seems to be more effective on TRPA1 than other types of
endotoxins [76]. Although previous studies demonstrate TRPA1 activation by LPS and its implication
in acute LPS-induced pain and neurogenic inflammation [5], the relative importance of TLR4 and
TRPA1 activation by LPS in our pneumonitis model remains to be elucidated.
The protective role of TRPA1 in the LPS-induced acute inflammatory processes including bronchial
hyperreactivity is supported by previous results of our group reporting similar protective actions of
capsaicin-sensitive sensory nerves and the TRPV1 receptor in the same model [77,78]. The similar
functions of TRPA1 and TRPV1 ion channels are not surprising, since they are often co-expressed and
interact with each other on the peptidergic sensory nerves [1,79]. The TRPA1-mediated protective effect
might be explained by the release of anti-inflammatory sensory neuropeptides from primary afferents,
such as somatostatin, similarly to the mechanism described earlier for TRPV1 activation [34,77].
TRPA1 proved to be protective against inflammatory bronchial hyperresponsiveness potentially
via smooth muscle relaxant neuropeptides released from the sensory nerves, despite its presence on
bronchial smooth muscle cells [47], which might directly lead to bronchoconstriction. Furthermore,
bronchodilator effects of TRPA1 activation via non-epithelial PGE2 production was recently reported
in allergic airway inflammation models [80]. Such mechanism might also be involved in our results.
A recent study also demonstrated significantly increased airway hyperresponsiveness in Trpv4 and
Trpa1/Trpv1 double knockout mice as well. The TRPV4 antagonist HC067047 administered to Trpa1/Trpv1
double knockout animals further increased the Penh value [81] supporting the protective role of these
TRP channels in the LPS-induced acute airway inflammation model.
TRPA1-deficiency did not significantly alter inflammatory cell numbers in the histopathological
pictures, but significantly increased neutrophil- and macrophage-derived MPO activity, which is
supported by TRPA1 expression on these cells [36,82]. The discrepancies between the histopathological
semiquantitative scores and the MPO activity might be due to the different sensitivity of the functional
and morphological assessments, however, it has also been described that MPO protein expression
itself might not correlate strongly with MPO activity due to genetic polymorphism or endogenous
inhibitors [83]. Consequently, increased ROS production might contribute to the increased bronchial
hyperreactivity in the Trpa1-deleted mice. These results are supported by earlier data that TRPA1
activation by irritants evokes defensive functions in the airways [54].
Despite these protective functions of TRPA1 in the acute LPS-evoked pneumonitis model,
TRPA1 activation is required for chronic CSE-evoked emphysema and respiratory deterioration, such as
MV, TV, PIF and PEF decrease with a peak after 3 months.
These data are supported by findings, that 4-week CSE increases TRPA1 mRNA level in the nodose
and jugular ganglia, positively correlating with the inflammatory cell infiltration in the BALF [84].
Moreover, cigarette smoke extract also increased the expression of TRPA1 in airway epithelial cells
in a hypoxia-inducible factor-1α-mediated manner [17,85]. Mostly in vitro data using cigarette
smoke extract are available about the role of TRPA1 in cigarette smoke-induced airway inflammation.
Isolated bronchi experiments suggested that cigarette smoke extract, as well as its components (acrolein
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and crotonaldehyde) caused Ca2+-dependent CGRP- and SP-release from the capsaicin-sensitive
nerve endings, and TRPA1 was involved in the cigarette smoke extract-induced tracheal plasma
extravasation and bronchoconstriction [6]. Cigarette smoke-induced CGRP release in the trachea were
predominantly mediated by TRPA1 rather than nicotinic receptors [9]. Cigarette smoke and acrolein
released keratinocyte chemoattractant (CXCL1/KC, mouse analogue of IL-8), which was attenuated
by TRPA1 antagonists and TRPA1-deficiency [47]. Furthermore, cigarette smoke extract-induced
and TRPA1-mediated IL-8 release was shown to develop via NADPH-oxidase activation and the
MAPKs/NFκB signaling pathway-related Ca2+ influx [17]. TRPA1 is involved in cigarette smoke
extract-evoked alveolar and bronchial epithelial damage [49]. Nicotine directly activates the TRPA1
receptor [8,10], which might mediate bronchoconstriction [47]. Similarly, ROS and several lipid
peroxidation products also stimulate TRPA1, which is likely to contribute to oxidative stress-evoked
airway pathologies induced by CSE [7,17,55], such as emphysema, for which we provided the first
data here.
The extent of perivascular/peribronchial oedema was the most severe after 1 month and gradually
decreasing afterwards, and the inflammatory cell infiltration reached its maximum after 2 months
of CSE in both groups, which is in agreement with our earlier findings in the same model [63].
TRPA1 deficiency did not result in significant changes of the cellular components of these chronic
inflammatory processes, as shown by both the histopathological results and BALF analysis.
Since the activation of TRPA1 exerts protective effects in LPS-induced acute pneumonitis and
subsequent bronchial hyperreactivity, our findings clearly support the concept that short-term activation
of TRPA1 results in defensive effects presumably via sensory nerves and consequently released
protective neuropeptides. However, permanent stimulation of the receptor under chronic inflammatory
conditions of the airways results in complex regulatory functions due to the diverse localization of
TRPA1 also on non-neural cells and its broad range of both exogenous and endogenous activators.
The genetic deletion of the receptor does not directly predict prophylactic or therapeutic potential
of TRPA1 agonists or antagonists. However, the activation of TRPA1 by commonly inhaled substances,
e.g., cinnamaldehyde or carvacrol [7] (components of cinnamon or thyme essential oils) could be
beneficial against acute inflammatory changes of the lung, additionally considering their antimicrobial
potentials against pathogens predominant in airway infections [86].
Therefore, further research is needed to determine TRPA1 potential as a pharmacological target in
the lung.
4. Methods
4.1. Animals
Experiments were performed on male and female Trpa1−/− mice and their Trpa1+/+ counterparts
(8–10 weeks, 20–25 g). The original heterozygote Trpa1+/− breeding pairs were a generous gift of
Pierangelo Geppetti (Firenze, Italy) [87]. The endotoxin-induced pneumonitis model was carried out
on female animals, while in the cigarette smoke-induced bronchitis model mice of both sexes were
used. Background strain of the gene-deleted animals was C57Bl/6, and the germline transmission of the
mutated allele and excision of the selection cassette were verified by PCR analysis. Animals were bred
and kept in the Laboratory Animal House of the Department of Pharmacology and Pharmacotherapy,
University of Pécs, Pécs, Hungary at 24–25 ◦C, provided with standard chow and water ad libitum and
maintained under a 12-h light–dark cycle.
4.2. Ethics
All experimental procedures were carried out according to the 40/2013 (II.14.) Government
Regulation on Animal Protection, Consideration Decree of Scientific Procedures of Animal Experiments
(243/1988) and Directive 2010/63/EU of the European Parliament. Studies were approved and a license
was given by the Ethics Committee on Animal Research of University of Pécs, Pécs, Hungary according
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to the Ethical Codex of Animal Experiments (licence No.: BA02/2000-35/2016, BA02/2000-26/2018).
We addressed the ARRIVE guidelines for designing, performing and reporting the experiments
wherever possible.
4.3. Endotoxin-Induced Acute Pneumonitis
Acute interstitial lung inflammation was evoked by intranasal (i.n.) administration of 60 µL,
167 µg/mL E. coli (serotype: O83) endotoxin (lipopolysaccharide, LPS) under light ether anaesthesia [77].
LPS was isolated and purified in the Department of Microbiology, University of Pécs, Pécs, Hungary [88].
Control animals received the same volume of sterile PBS.
Endotoxin is a component of the cell wall of Gram-negative bacteria, composed of a
phosphoglycolipid (lipid A) covalently bound to a hydrophilic heteropolysaccharide part [89].
LPS—connected to the specific LPS binding protein (LBP)—is able to bind to Toll-like receptor
4 (TLR4)-CD14 glycoprotein complex expressed on macrophages and monocytes [90]. Via the
p38-MAPK signaling pathway it induces the activation and accumulation of immune cells [91,92]. As a
result, inflammatory cytokines and proinflammatory mediators (e.g., bradykinin, leukotrienes and
prostaglandins) are released from the activated immune cells directly activating the sensory nerve
endings [93]. Beside the activation of immune cells, LPS also elicits bronchial contraction in the lung
causing enhanced airway resistance [94].
4.4. Cigarette Smoke-Induced Chronic Airway Inflammation
Chronic bronchitis was elicited by whole body cigarette smoke exposure for 4 months. Mice were
exposed to cigarette smoke (3R4F Kentucky Research Cigarette; University of Kentucky, Lexington, KY,
USA) twice daily, 10 times per week in a whole body smoke exposure chamber (Teague Enterprises,
Woodland, CA, USA) for 30 min followed by a ventilation period of 30 min as described previously [63].
4.5. Investigation of Airway Function and Bronchial Responsiveness
Parameters of the airway function were measured in conscious, spontaneously breathing mice
with the help of unrestrained whole-body plethysmography (Buxco Europe Ltd., Winchester, UK).
In the endotoxin-induced acute pneumonitis model, breathing frequency (f) and carbachol-induced
airway reactivity were measured before and 24 h after intranasal PBS/LPS administration [95].
Bronchoconstriction was induced by increasing concentrations (5.5, 11 and 22 mM) of the muscarinic
receptor agonist carbachol (50 µL/mouse), and the Penh (enhanced pause) value was determined.
Penh is a complex calculated parameter ((expiratory time/relaxation time) − 1)/(max. expiratory
flow/max. inspiratory flow), well correlating with bronchoconstriction and airway resistance measured
in ventilated animals using invasive techniques [34].
Considering that cigarette smoke-induced chronic bronchitis model is a disease model with high
translational relevance, we performed an extended analysis of the respiratory functions determining f,
TV, MV, Ti, Te, RT, PIF, PEF and Penh before and at the end of every month of the 4-month-investigational
period as described previously [63].
4.6. Cell Composition Analysis of the Bronchoalveolar Lavage Fluid (BALF)
In the cigarette smoke exposure model, mice were anaesthetised with ketamine and xylazine
(100 mg/kg and 5 mg/kg, s.c., respectively) and the lungs were washed with 5 mL PBS. BALF was
collected in centrifuge tubes (1000 rpm, 5 min) and the supernatants were removed. Cells were
resuspended in staining buffer (0.1% NaN3 and 0.1% BSA dissolved in 500 µL PBS), and 1 µL CD45
fluorescein-5-isothiocyanate (FITC) solution was given to the samples. After incubation of 30 min, 1 µL
propidium-iodide was given to the samples and after centrifugation (1000 rpm, 5 min) the supernatant
was removed again. Cells were resuspended in fixation buffer (3% formaldehyde dissolved in 700 µL
PBS) and the cell profile of the samples was analysed with a CyFlow Space flow cytometer (Sysmex
Partec, Münster, Germany) [96].
Int. J. Mol. Sci. 2020, 21, 4109 15 of 21
We previously showed that in the CSE model perivascular/peribronchial oedema developed
in the 1st month, while in the 2nd and 3rd months inflammatory cell infiltration dominated the
histopathological picture, which decreased by the 4th month accompanied by tissue destruction [63].
Based on these data, we investigated the amount of inflammatory cells in the BALF after the 2nd and
3rd months.
4.7. Histological Examination of the Lungs
In both models, lungs were removed following cervical dislocation in deep anaesthesia. The left
lung was fixed in 4% formaldehyde and embedded in paraffin for histopathological processing.
Sections were made with 5–7 µm microtome and stained with hematoxylin-eosin (HE). One section of
the lungs of the endotoxin-treated mice was stained with periodic acid-Schiff (PAS) reagent in order to
visualize mucus producing goblet cells. Semiquantitative evaluation of the histological alterations was
performed by an expert pathologist blinded from the experimental design.
In the acute pneumonitis model, semiquantitative histopathological scoring of the lungs was
performed based on the following parameters: perivascular oedema (0–3), accumulation of the
perivascular and peribonchial neutrophil granulocytes (0–3), infiltration of activated macrophages and
mononuclear cells into the alveolar space (0–2), as well as hyperplasia of the bronchiolar goblet cells
(0–2) [97]. The composite inflammatory score (ranging between 0 and 10) was generated by addition of
the individual histopathological parameters.
In the chronic COPD model, semiquantitative histopathological scoring of the lungs was established
by our work group and performed on the basis of perivascular oedema, the accumulation of
neutrophil granulocytes into the perivascular/peribronchial and interstitial space, as well as the
perivascular/peribronchial and interstitial infiltration of macrophages and lymphocytes with scores
ranging from 0–3 (0: intact, 0.5: focal mild, 1: diffuse mild, 1.5: focal moderate, 2: diffuse moderate, 2.5:
focal severe, 3: diffuse severe).
Quantitative histopathological evaluation of emphysema was performed by the measurement of
the mean linear intercept as described previously [98]. Briefly, air space enlargement was assessed
by the measurement of the alveolar space or alveolar and ductal air space along parallel lines
on approximately 400,000 µm2 representative areas on each slide by The Case Viewer software
(3DHISTECH, Budapest, Hungary).
4.8. Morphological Evaluation of the Lungs with In Vivo MicroCT Investigation
In the cigarette smoke exposure model, structural alterations, such as the LAA/TLV% characteristic
to emphysema was also measured by in vivo microCT in a self-controlled manner, before, as well as 2
and 4 months after CSE exposure as described previously [63]. Briefly, mice were anaesthetized with
pentobarbital (70 mg/kg) i.p. and their lungs were imaged by breath-gated tomography on a Skyscan
1176 high resolution microtomograph (Skyscan, Kontich, Belgium). Reconstruction and morphometric
analysis were performed with the software provided by the manufacturer.
4.9. Determination of Myeloperoxidase (MPO) Activity from Lung Homogenates with Spectrophotometry
During the evolvement of endotoxin-induced acute pneumonitis, MPO enzyme is produced by
the accumulated neutrophil granulocytes, monocytes and macrophages [99]. The MPO activity of the
lung homogenates were measured by spectrophotometry using H2O2-3,3′,5,5′-tetramethyl-benzidine
(TMB/H2O2) and compared to a standard MPO preparation as described earlier [98].
4.10. Statistical Analysis
Statistical analysis was performed by the GraphPad Prism v6 software (GraphPad Software,
San Diego, CA, USA). Comparison of basal respiratory functions of intact wildtype and TRPA-deficient
mice was performed by a Student’s t-test for unpaired comparison. Parameters of the respiratory
function in both the LPS and CSE study, as well as LAA/TLV%, mean linear intercept, and BALF
Int. J. Mol. Sci. 2020, 21, 4109 16 of 21
inflammatory cell counts were evaluated by two-way ANOVA followed by Tukey’s post hoc test.
MPO activity was analysed by one-way ANOVA followed by Bonferroni’s post-test. Histopathological
semiquantitative scores were evaluated by Kruskal–Wallis analysis followed by Dunn’s post-test. In all
cases p < 0.05 was accepted as significant.
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